gs-441524
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2021 (NCT04859244)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- MarburgvirusINHIBITOR
Marburgvirus inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
N#C[C@@]1(c2ccc3c(N)ncnn23)O[C@H](CO)[C@@H](O)[C@H]1O- Mol. weight
- 291.27 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2016757 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06274853 | Phase 1 | Jun 15, 2024 | Leidos, National Center for Advancing Translational Science (NCATS) |
| NCT04859244 | Phase 1 | Jan 1, 2021 | Copycat Sciences LLC |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Copycat Sciences LLC | For profit | 1 | 1 | 1 | 2021 |
| Leidos | For profit | 1 | 0 | 1 | 2024 |
| National Center for Advancing Translational Science (NCATS) | Government | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1